-+ 0.00%
-+ 0.00%
-+ 0.00%

IN8bio Announces Patient 009 In Phase 1 Trial Of INB-200 For Newly-Diagnosed GBM Reaches Significant Clinical Milestone

Benzinga·06/09/2025 11:06:50
Listen to the news

IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recently reached a significant clinical milestone. The patient, with a grade 4, IDH-mutant glioma, has been in remission and surviving for 4 years having been treated with INB-200. The patient is doing well, has returned to work and has a good quality of life post-treatment with INB-200. Patient 009's clinical progress and 4-year remission far surpasses progression-free outcomes observed in other clinical trials of IDH-mutant glioma patients.